Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia (case series)
N = 24
- Population
- Patients with APL: 16 previously untreated and 8 nonresponsive or resistant to previous chemotherapy
- Design
- Uncontrolled treatment series reported in an abstract; phase and route of administration are not stated in the abstract.
- Arms
- All-trans retinoic acid (experimental, n = 24): All-trans retinoic acid, 45 to 100 mg/m2/day
- People
- Huang ME
Show the numbers
| Endpoint | Analysis | All-trans retinoic acid | Control | Effect |
|---|---|---|---|---|
| Complete remission rateAll 24 treated patients | primaryHuang 1988 | 100% | — | 24 of 24 patients; the abstract also states that remission occurred without bone marrow hypoplasia. One patient whose cells did not respond to retinoic acid in culture was resistant to it clinically but attained complete remission after low-dose cytarabine was added. Eight patients relapsed after 2 to 5 months of complete remission; the others remained in complete remission at 1+ to 11+ months at the time of writing. |
| Endpoint | Analysis | All-trans retinoic acid | Control | Effect |
|---|---|---|---|---|
| Complete remission rateAll 24 treated patients | primaryHuang 1988 | 100% | — | 24 of 24 patients; the abstract also states that remission occurred without bone marrow hypoplasia. One patient whose cells did not respond to retinoic acid in culture was resistant to it clinically but attained complete remission after low-dose cytarabine was added. Eight patients relapsed after 2 to 5 months of complete remission; the others remained in complete remission at 1+ to 11+ months at the time of writing. |
Appears in
Sources
Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567-72.